Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25973017 | 1.00 | SCN9A (0.46) | SCN9AKDM1AMEN1KMT2ACHRM5 | |
| SCHEMBL9634176 | 0.95 | KDM1A (0.43) | SCN9AKDM1AMEN1KMT2AMTNR1A | |
| SCHEMBL28905130 | 0.83 | NR1H4 (0.39) | SCN9AMEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL28521104 | 0.81 | CHRNA7 (0.53) | SCN9AMEN1KMT2ACHRM5CHRM3 | |
| SCHEMBL27761854 | 0.79 | MEN1 (0.41) | MEN1KMT2ACHRM5CHRM3CHRM1 | |
| SCHEMBL6806512 | 0.79 | MAPT (0.41) | MEN1KMT2ACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL27999354 | 0.79 | KDM1A (0.52) | KDM1AMTNR1AIDO1CYP2D6SLC6A2 | |
| SCHEMBL13811323 | 0.79 | KDM1A (0.52) | KDM1AMTNR1AIDO1CYP2D6SLC6A2 | |
| SCHEMBL1638187 | 0.77 | CYP2D6 (0.47) | KDM1AMTNR1AIDO1CYP2D6SLC6A2 | |
| SCHEMBL1763476 | 0.77 | KDM1A (0.50) | KDM1AMTNR1AIDO1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244670-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL Holdings, Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| WO-2001046195-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL HOLDINGS, INC. (US) | 2001-06-28 | — | — | WO | claimed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-115161672-B | Method for electrochemical synthesis of amino (dithioperoxy) thiocarboxylate compound | 广西师范大学 | 2024-04-16 | — | — | CN | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11420968-B2 | Bcl-2 inhibitors | BEIGENE, LTD. (KY) | 2022-08-23 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1879863-A1 | AMIDE RESORCINOL COMPOUNDS | Pfizer, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117669-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1244670-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL Holdings, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001046195-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL HOLDINGS, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | SCN9A 3234/4885KDM1A 2400/4885MEN1 3803/4885 |
| US-11420968-B2 | Bcl-2 inhibitors | BCL2, BCL2L1, BCL2L2 | SCN9A 3234/4885KDM1A 2400/4885MEN1 3803/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | SCN9A 3234/4885KDM1A 2400/4885MEN1 3803/4885 |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | SCN9A 1327/4885KDM1A 3561/4885MEN1 4482/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | SCN9A 3234/4885KDM1A 2400/4885MEN1 3803/4885 |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | SCN9A 4763/4885KDM1A 4158/4885MEN1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.